Medincell, a biotechnology company specializing in long-acting injectable treatments, will participate in the 8th Annual Evercore Healthcare Conference in Miami and the 37th Annual Piper Sandler Healthcare Conference in New York. These events will take place from December 2 to December 4, 2025. Christophe Douat, CEO, Dr. Richard Malamut, Medical Director, and Dr. Grace Kim, Chief Strategy Officer, U.S. Finance, will represent Medincell at these conferences.
Presentation Schedule
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
According to the press release, Medincell will present its advancements on December 3 at 3:35 PM Paris time at the Evercore Healthcare Conference and on December 4 at 5:00 PM Paris time at the Piper Sandler Healthcare Conference. Meetings with the management can also be arranged through Medincell or its banking representatives.
Company Profile
Based in Montpellier, Medincell develops injectable treatments using its BEPO technology for prolonged drug release. Their products include risperidone LAI, approved for schizophrenia and bipolar I disorder in the U.S. The company collaborates with various partners to offer new therapeutic options and employs over 140 people.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
